Department of Biochemistry and Biophysics, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-3290, USA.
Mol Pharmacol. 2010 Apr;77(4):508-16. doi: 10.1124/mol.109.062356. Epub 2010 Jan 5.
Organophosphorus (OP) nerve agents are potent toxins that inhibit cholinesterases and produce a rapid and lethal cholinergic crisis. Development of protein-based therapeutics is being pursued with the goal of preventing nerve agent toxicity and protecting against the long-term side effects of these agents. The drug-metabolizing enzyme human carboxylesterase 1 (hCE1) is a candidate protein-based therapeutic because of its similarity in structure and function to the cholinesterase targets of nerve agent poisoning. However, the ability of wild-type hCE1 to process the G-type nerve agents sarin and cyclosarin has not been determined. We report the crystal structure of hCE1 in complex with the nerve agent cyclosarin. We further use stereoselective nerve agent analogs to establish that hCE1 exhibits a 1700- and 2900-fold preference for the P(R) enantiomers of analogs of soman and cyclosarin, respectively, and a 5-fold preference for the P(S) isomer of a sarin analog. Finally, we show that for enzyme inhibited by racemic mixtures of bona fide nerve agents, hCE1 spontaneously reactivates in the presence of sarin but not soman or cyclosarin. The addition of the neutral oxime 2,3-butanedione monoxime increases the rate of reactivation of hCE1 from sarin inhibition by more than 60-fold but has no effect on reactivation with the other agents examined. Taken together, these data demonstrate that hCE1 is only reactivated after inhibition with the more toxic P(S) isomer of sarin. These results provide important insights toward the long-term goal of designing novel forms of hCE1 to act as protein-based therapeutics for nerve agent detoxification.
有机磷(OP)神经毒剂是强效毒素,可抑制胆碱酯酶并产生快速和致命的拟胆碱能危机。正在开发基于蛋白质的治疗药物,以防止神经毒剂毒性并防止这些药物的长期副作用。药物代谢酶人羧基酯酶 1(hCE1)是一种候选的基于蛋白质的治疗药物,因为它在结构和功能上与神经毒剂中毒的胆碱酯酶靶标相似。然而,尚未确定野生型 hCE1 处理 G 型神经毒剂沙林和环沙林的能力。我们报告了 hCE1 与神经毒剂环沙林复合物的晶体结构。我们进一步使用立体选择性神经毒剂类似物来确定 hCE1 对沙林和环沙林类似物的 P(R)对映体分别表现出 1700 倍和 2900 倍的偏好,并且对沙林类似物的 P(S)异构体表现出 5 倍的偏好。最后,我们表明对于被真正的神经毒剂混合物抑制的酶,hCE1 在存在沙林的情况下会自发重新激活,但在存在沙林或环沙林的情况下不会重新激活。中性肟 2,3-丁二酮单肟的添加使 hCE1 从沙林抑制中重新激活的速率提高了 60 多倍,但对用其他检查的药物进行的重新激活没有影响。总之,这些数据表明,hCE1 仅在被更毒的 P(S)异构体沙林抑制后才会被重新激活。这些结果为设计新型 hCE1 形式作为神经毒剂解毒的基于蛋白质的治疗药物的长期目标提供了重要的见解。